RecruitingNCT02753777

Autoimmune Blistering Diseases Study

Prevalence and Clinical Severity of Autoimmune Blistering Diseases

Sponsor

University of Pennsylvania

Enrollment

150 participants

Start Date

Apr 1, 2016

Study Type

OBSERVATIONAL

Conditions

Bullous pemphigoid Pemphigus Vulgaris Pemphigus Foliaceus

Summary

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood and tissue samples from patients with autoimmune blistering skin diseases — specifically pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. These conditions cause the immune system to attack the skin and mucous membranes, creating painful blisters. The research aims to understand the biology of these diseases and develop better treatments. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid - You are able to provide informed consent You may NOT be eligible if: - You are under 18 years of age - You do not have pemphigus or pemphigoid - You are a Penn (University of Pennsylvania) employee or student - You have cognitive impairment that prevents providing informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.